Introduction {#sec1}
============

Increasing studies have demonstrated that a number of proinflammatory cytokines could be associated with the development of cancer \[[@B1],[@B2]\]. Lymphotoxin-α (LTA) is the predominant member of the tumor necrosis factor (TNF) ligand family, which responds to immune and inflammatory reaction and plays an important role in the pathogenesis of cancer \[[@B3],[@B4]\]. The human *LTA* gene is located on the short arm of chromosome 6 (6p21.3) \[[@B5]\]. The presence of single nucleic polymorphism (SNP) may affect cytokine expression level, which might be an important mediator of cancer \[[@B6],[@B7]\]. SNP rs1041981 is a mutation of *LTA* gene at the 804 (C/A) position of exon 3 in codon 26, causing the amino acid threonine to be asparagine, which may be related to the transcriptional regulation of *LTA*, then activate the lymphocytes and induce apoptosis \[[@B8]\]. While, SNP rs909253 is a mutation of *LTA* gene at 252 (A/G) position in intron 1, which may lead to increase in the transcriptional activities of *LTA* \[[@B1]\]. In addition, SNP rs2239704, rs746868 and rs2229094 are associated with the *LTA* expression, which may affect subsequent inflammatory responses and immunomodulatory diseases, including cancers \[[@B9],[@B10]\].

There are ample evidences that have demonstrated the association between *LTA* polymorphisms and cancer \[[@B11]\]. However, these results are inconsistent and even contradictory, which might be due to the heterogeneity within cancer types, ethnicities, source of control, Hardy--Weinberg equilibrium (HWE), small sample sizes and so on. Huang et al. reported a meta-analysis about this topic, and they found that the *LTA* rs1041981, rs2239704 and rs2229094 polymorphisms were associated with the increased risk of cancers \[[@B35]\]. However, based on the current studies, we found that more studies were negatively correlated with *LTA* polymorphisms and cancer \[[@B11],[@B13],[@B18],[@B27],[@B28],[@B31],[@B32]\]. Therefore, we conducted the current updated systematic review and meta-analysis to accurately determine the association between genetic variation of *LTA* gene and cancer susceptibility.

Materials and methods {#sec2}
=====================

Literature search {#sec2-1}
-----------------

We conducted a systematic literature search on PubMed, Medline, Embase, Google Scholar and Web of Science to retrieve all eligible publications on the association between *LTA* polymorphisms and the risk of cancer (up to 28 February 2020) with the following keywords: (LTA OR Lymphotoxin alpha OR TNF-β OR tumor necrosis factor-beta) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (cancer OR tumor OR neoplasm OR malignancy OR carcinoma OR adenocarcinoma). The language of enrolled studies was restricted to English. After carefully screening, five polymorphisms were left for further investigation.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Articles enrolled in our meta-analysis satisfied the following inclusion criteria: (1) case--control studies that evaluated the association between *LTA* polymorphisms and cancer risk; (2) publications focusing on population genetic polymorphisms; (3) articles with sufficient genotype data to assess odds ratios (ORs) and the corresponding 95% CIs; (4) blood sample only for SNP analysis; (5) the control subjects satisfied HWE. The major exclusion criteria were: (1) case-only studies, case reports or reviews; (2) studies without raw data for the LTA genotype.

Data extraction {#sec2-3}
---------------

Two investigators (Jingdong Li and Yaxuan Wang) independently extracted the data from each study. All the case--control studies satisfied the inclusion criteria and consensus for any controversy was achieved. The data from the eligible articles comprise the first author's name, year of publication, ethnicity, source of control, cancer type and numbers of cases and controls in *LTA* genotypes. Ethnicity was categorized as 'Asian', 'Caucasian', and 'Mixed'.

Statistical analysis {#sec2-4}
--------------------

The risk between the *LTA* polymorphisms and cancer was evaluated using summary ORs and the corresponding 95% CIs in allelic (B vs. A), dominant (BA + BB vs. AA), and recessive (BB vs. BA + AA) models (A: wild allele; B: mutated allele). The Cochrane's Q-statistic test was used to assess the heterogeneity between studies, and the inconsistency was quantified with the *I^2^* statistic. The substantial heterogeneity was considered significant when *I^2^* \> 50% or PQ ≤ 0.1, then, a random-effects model was used; otherwise, the fixed-effects model was applied. Subgroup meta-analysis were performed by cancer type, ethnicity, genotyping, HWE and the source of control. We also conducted sensitivity analysis to assess stability of the results by omitting one study each time to exclude studies. HWE was estimated by the asymptotic test, and deviation was considered when *P*\<0.05. The potential publication bias of the eligible studies was evaluated by Begg's and Egger's regression test quantitatively. Trial sequential analysis (TSA) was performed as described by Xie et al. \[[@B36]\]. The required information size was calculated after adopting a level of significance of 5% for type I error and of 30% for type II error. The data was analyzed using the Stata 14.0 software (version 14.0; State Corporation, College Station, Texas, U.S.A.). A two-tailed *P*\<0.05 was considered statistically significant.

Results {#sec3}
=======

Main characteristics of the enrolled studies {#sec3-1}
--------------------------------------------

The study selection processes were presented in [Figure 1](#F1){ref-type="fig"}. For polymorphisms of *LTA* gene (rs1041981, rs2229094, rs2239704, rs746868, rs909253), a total of 24 articles (including 43 case--control studies) with 24577 cases and 33351 controls met the inclusion criteria \[[@B11]\]. Sixteen of these studies were performed in Asians, 17 studies were performed in Caucasians, 10 studies in Africans and the others were in mixed ethnic groups (including at least one race). Controls of 30 studies were population-based controls and 13 studies were hospital-based controls. All studies were in compliance with HWE except for two studies \[[@B30],[@B32]\]. [Table 1](#T1){ref-type="table"} shows the characteristics of all the eligible studies and genotype frequency distributions of the five *LTA* polymorphisms included in our meta-analysis. Newcastle--Ottawa scale (NOS) was used to evaluate the quality of the enrolled studies, as shown in [Table 2](#T2){ref-type="table"}.

![Flow chart of studies selection process for *LTA* gene polymorphisms](bsr-40-bsr20192320-g1){#F1}

###### Characteristics of the enrolled studies

  SNP         First author      Year   Ethnicity   Source of control   Cancer type   Case   Control   HWE                       
  ----------- ----------------- ------ ----------- ------------------- ------------- ------ --------- ----- ------ ------ ----- ---
  rs1041981   Abbas             2010   Caucasian   PB                  OC            1498   1317      332   2481   2399   607   Y
              Castro            2009   Caucasian   PB                  OC            154    456       341   337    813    557   Y
              Lee               2004   Asian       PB                  GC            109    156       63    74     132    47    Y
              Niwa              2005   Asian       HB                  OC            60     59        12    107    165    48    Y
              Niwa              2007   Asian       HB                  OC            51     43        16    71     114    35    Y
              Sainz             2012   Caucasian   PB                  OC            833    729       198   794    760    173   Y
  rs2229094   Abbas             2010   Caucasian   PB                  OC            1686   1199      251   2965   2153   359   Y
              Madeleine         2011   Mixed       PB                  OC            444    329       75    475    334    57    Y
              Mahajan           2008   Caucasian   PB                  GC            206    74        21    247    150    18    Y
              Wang              2009   Mixed       PB                  NHL           1043   751       148   978    702    124   Y
  rs2239704   Cerhan            2008   Mixed       HB                  NHL           169    217       55    170    225    79    Y
              Ennas             2008   Caucasian   PB                  OC            14     17        7     36     53     23    Y
              Gu                2014   Asian       PB                  NHL           33     50        10    82     96     25    Y
              Gu                2014   Asian       PB                  NHL           30     21        13    82     100    47    Y
              Lan               2006   Mixed       PB                  NHL           165    189       63    186    226    87    Y
              Mahajan           2008   Caucasian   PB                  GC            85     138       76    105    223    85    Y
              Purdue            2007   Caucasian   HB                  NHL           202    240       64    162    229    72    Y
              Wang              2009   Mixed       PB                  NHL           697    754       241   599    714    256   Y
  rs746868    Crusius           2008   Caucasian   PB                  GC            151    205       72    398    545    181   Y
              Garcia-Gonzalez   2007   Caucasian   PB                  GC            135    194       75    142    191    71    Y
              Gunter            2006   Mixed       HB                  OC            85     107       27    76     102    27    Y
              Mahajan           2008   Caucasian   PB                  GC            83     143       74    108    220    84    Y
  rs909253    Cerhan            2008   Mixed       HB                  NHL           179    208       53    207    217    51    Y
              Cheng             2015   Asian       HB                  NHL           45     71        9     95     149    56    Y
              Crusius           2008   Caucasian   PB                  GC            168    218       38    533    472    121   Y
              Ennas             2008   Caucasian   PB                  OC            29     10        1     85     24     4     Y
              Garcia-Gonzalez   2007   Caucasian   PB                  GC            238    127       39    222    154    28    Y
              Gu                2014   Asian       PB                  NHL           42     39        11    69     98     36    Y
              Gu                2014   Asian       PB                  NHL           27     29        8     104    97     28    Y
              Gunter            2006   Mixed       HB                  OC            90     101       35    88     92     29    Y
              Jeng              2014   Asian       PB                  HCC           46     65        39    98     42     10    Y
              Lakhanpal         2016   Asian       HB                  OC            14     59        47    39     24     37    N
              Lan               2006   Mixed       PB                  NHL           240    218       59    274    254    65    Y
              Lee               2004   Asian       PB                  GC            112    152       64    77     131    46    Y
              Liu               2013   Asian       PB                  NHL           111    151       29    95     149    56    Y
              Mahajan           2008   Caucasian   PB                  GC            137    135       29    201    174    38    Y
              Mou               2015   Asian       HB                  GC            105    75        14    57     48     28    N
              Niwa              2005   Asian       HB                  OC            60     59        12    107    165    48    Y
              Niwa              2007   Asian       HB                  OC            51     43        16    71     114    35    Y
              Purdue            2007   Caucasian   HB                  NHL           205    265       68    198    233    63    Y
              Tsai              2017   Asian       PB                  HCC           45     66        39    98     42     10    Y
              Wang              2009   Mixed       PB                  NHL           778    857       262   788    766    219   Y
              Yri               2013   Caucasian   PB                  NHL           157    247       76    394    479    136   Y

Abbreviations: GC, gastric cancer; HB, hospital-based; HCC, hepatocellular carcinoma; N, no; NHL, non-Hodgkin lymphoma; OC, other cancer; PB, population-based; Y, yes.

###### Methodological quality of the enrolled studies according to the NOS

  SNP         First author             Adequacy definition   Representativeness of the cases   Control selection   Control definition   Comparability cases/ controls   Exposure ascertainment   Same method ascertainment   Non-response rate
  ----------- ------------------------ --------------------- --------------------------------- ------------------- -------------------- ------------------------------- ------------------------ --------------------------- -------------------
  rs1041981   Abbas et al.             \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Castro et al.            \*                    \*                                \*                  \*                   \*\*                            \*\*                     \*                          \*
              Lee et al.               \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Niwa et al.              \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Niwa et al.              \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Sainz et al.             \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
  rs2229094   Abbas et al.             \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Madeleine et al.         \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Mahajan et al.           \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Wang et al.              \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
  rs2239704   Cerhan et al.            \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Ennas et al.             \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Gu et al.                \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Gu et al.                \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Lan et al.               \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Mahajan et al.           \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Purdue et al.            \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Wang et al.              \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
  rs746868    Crusius et al.           \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Garcia-Gonzalez et al.   \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Gunter et al.            \*                    \*                                NA                  \*                   \*\*                            \*\*                     \*                          \*
              Mahajan et al.           \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
  rs909253    Cerhan et al.            \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Cheng et al.             \*                    \*                                NA                  \*                   \*\*                            \*\*                     \*                          \*
              Crusius et al.           \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Ennas et al.             \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Garcia-Gonzalez et al.   \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Gu et al.                \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Gu et al.                \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Gunter et al.            \*                    \*                                NA                  \*                   \*\*                            \*\*                     \*                          \*
              Jeng et al.              \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Lakhanpal et al.         \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Lan et al.               \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Lee et al.               \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Liu et al.               \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Mahajan et al.           \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Mou et al.               \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Niwa et al.              \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Niwa et al.              \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Purdue et al.            \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*
              Tsai et al.              \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Wang et al.              \*                    \*                                \*                  \*                   \*\*                            \*                       \*                          \*
              Yri et al.               \*                    \*                                NA                  \*                   \*\*                            \*                       \*                          \*

A study can be awarded a maximum of one star (\*) for each numbered item within the Selection and Exposure categories. A maximum of two stars (\*\*) can be given for Comparability. Abbreviations: NA, not applicable.

Quantitative synthesis {#sec3-2}
----------------------

***rs1041981***

The pooled results based on six included studies \[[@B11]\] (including 6427 cases and 9714 controls) indicated that no significant association between rs1041981 polymorphism and cancer risk was found. However, in the stratification analysis by ethnicity, we observed that Asian group was significantly related to a reduced risk of cancer in allelic contrast (B vs A: OR = 0.79, 95% confidence interval (CI) = 0.64--0.97, *P*=0.027, [Figure 2](#F2){ref-type="fig"}) and dominant model (BB+AB vs AA: OR = 0.67, 95% CI = 0.52--0.87, *P*=0.002). Moreover, when the subgroup analysis was performed based on source of controls, hospital-based control group was significantly related to a decreased risk of cancer in allelic contrast (B vs A: OR = 0.69, 95% CI = 0.55--0.87, *P*=0.002) and dominant model (BB+AB vs AA: OR = 0.58, 95% CI = 0.42--0.78, *P*=0.000) ([Table 3](#T3){ref-type="table"}).

![Forest plot of *LTA* rs1041981 polymorphism and cancer risk in allelic contrast stratified by ethnicity](bsr-40-bsr20192320-g2){#F2}

###### Meta-analysis of rs1041981

  Variables           *n*   Allelic contrast           Dominant model   Recessive model                                                      
  ------------------- ----- -------------------------- ---------------- -------------------------- -------------- -------------------------- --------------
  Total               6     0.307, 0.94 (0.84, 1.06)   0.002, 73.1%     0.163, 0.89 (0.75, 1.05)   0.002, 73.1%   0.607, 1.03 (0.91, 1.17)   0.214, 29.4%
  Ethnicity                                                                                                                                  
  Asian               3     0.027, 0.79 (0.64, 0.97)   0.192, 39.4%     0.002, 0.67 (0.52, 0.87)   0.303, 16.2%   0.433, 0.87 (0.63, 1.22)   0.327, 10.5%
  Caucasian           3     0.782, 1.02 (0.91, 1.14)   0.009, 78.7%     0.951, 1.01 (0.85, 1.18)   0.014, 76.4%   0.380, 1.06 (0.93, 1.22)   0.152, 47.0%
  Source of control                                                                                                                          
  PB                  4     0.926, 1.00 (0.91, 1.11)   0.022, 68.7%     0.788, 0.98 (0.85, 1.13)   0.029, 66.8%   0.329, 1.06 (0.95, 1.18)   0.287, 20.5%
  HB                  2     0.002, 0.69 (0.55, 0.87)   0.774, 0.0%      0.000, 0.58 (0.42, 0.78)   0.813, 0.0%    0.171, 0.72 (0.46, 1.15)   0.336, 0.0%

Abbreviations: HB, hospital-based; *n*, number; PB, population-based.

### rs2229094 {#sec3-2-1}

The pooled results based on four included studies \[[@B11],[@B17]\] (including 6227 cases and 8562 controls) indicated that no significant association between rs2229094 polymorphism and cancer risk was found. Further subgroup analysis by ethnicity also indicated that no significant result was uncovered (Supplementary Table S1).

### rs2239704 {#sec3-2-2}

The pooled results based on eight included studies \[[@B18]\] (including 3550 cases and 3962 controls) suggested that rs2239704 reduced the risk of cancer in allelic contrast (B vs A: OR = 0.90, 95% CI = 0.85--0.97, *P*=0.003), dominant model (BB+AB vs AA: OR = 0.88, 95% CI = 0.80--0.96, *P*=0.006) and recessive model (BB vs AA+AB: OR = 0.88, 95% CI = 0.77--0.99, *P*=0.040). Furthermore, in the stratification analysis by cancer type, we observed that rs2239704 reduced the risk of NHL in allelic contrast (B vs A: OR = 0.89, 95% CI = 0.83--0.96, *P*=0.001, [Figure 3](#F3){ref-type="fig"}), dominant model (BB+AB vs AA: OR = 0.88, 95% CI = 0.80--0.97, *P*=0.011) and recessive model (BB vs AA+AB: OR = 0.83, 95% CI = 0.72--0.95, *P*=0.006). Moreover, when the subgroup analysis was performed based on ethnicity, source of control and genotyping, we found mixed ethnicity was significantly related to a reduced risk of cancer in allelic contrast (B vs A: OR = 0.89, 95% CI = 0.83--0.97, *P*=0.006), dominant model (BB+AB vs AA: OR = 0.89, 95% CI = 0.79--1.00, *P*=0.042) and recessive model (BB vs AA+AB: OR = 0.82, 95% CI = 0.71--0.96, *P*=0.013) ([Table 4](#T4){ref-type="table"}).

![Forest plot of *LTA* rs2239704 polymorphism and cancer risk in allelic contrast stratified by cancer type\
Abbreviations: GC, gastric cancer; OC, other cancer.](bsr-40-bsr20192320-g3){#F3}

###### Meta-analysis of rs2239704

  Variables           *n*   Allele contrast            Dominant model   Recessive model                                                      
  ------------------- ----- -------------------------- ---------------- -------------------------- -------------- -------------------------- --------------
  Total               8     0.003, 0.90 (0.85, 0.97)   0.819, 0.0%      0.006, 0.88 (0.80, 0.96)   0.831, 0.0%    0.040, 0.88 (0.77, 0.99)   0.444, 0.0%
  Cancer type                                                                                                                                
  NHL                 6     0.001, 0.89 (0.83, 0.96)   0.876, 0.0%      0.011, 0.88 (0.80, 0.97)   0.626, 0.0%    0.006, 0.83 (0.72, 0.95)   0.958, 0.0%
  GC                  1     0.733, 1.04 (0.84, 1.28)   NA               0.371, 0.86 (0.61, 1.20)   NA             0.128, 1.32 (0.92, 1.87)   NA
  OC                  1     0.605, 0.87 (0.51, 1.47)   NA               0.596, 0.81 (0.38, 1.75)   NA             0.778, 0.87 (0.34, 2.24)   NA
  Ethnicity                                                                                                                                  
  Asian               2     0.633, 0.94 (0.72, 1.22)   0.264, 19.8%     0.645, 0.92 (0.63, 1.33)   0.084, 66.5%   0.775, 0.93 (0.55, 1.55)   0.791, 0.0%
  Caucasian           3     0.227, 0.92 (0.81, 1.05)   0.356, 3.3%      0.061, 0.83 (0.68, 1.01)   0.964, 0.0%    0.924, 1.01 (0.79, 1.29)   0.131, 50.8%
  Mixed               3     0.006, 0.89 (0.83, 0.97)   0.944, 0.0%      0.042, 0.89 (0.79, 1.00)   0.978, 0.0%    0.013, 0.82 (0.71, 0.96)   0.698, 0.0%
  Source of control                                                                                                                          
  PB                  6     0.033, 0.92 (0.85, 0.99)   0.728, 0.0%      0.029, 0.88 (0.79, 0.99)   0.681, 0.0%    0.258, 0.92 (0.80, 1.06)   0.431, 0.0%
  HB                  2     0.022, 0.86 (0.75, 0.98)   0.849, 0.0%      0.095, 0.85 (0.71, 1.03)   0.581, 0.0%    0.029, 0.75 (0.58, 0.97)   0.710, 0.0%
  Genotyping                                                                                                                                 
  PCR                 5     0.023, 0.91 (0.85, 0.99)   0.546, 0.0%      0.032, 0.89 (0.79, 0.99)   0.548, 0.0%    0.153, 0.90 (0.78, 1.04)   0.174, 37.0%
  TaqMan              3     0.041, 0.88 (0.77, 0.99)   0.877, 0.0%      0.087, 0.85 (0.71, 1.02)   0.830, 0.0%    0.110, 0.82 (0.64, 1.05)   0.955, 0.0%

Abbreviations: GC, gastric cancer; HB, hospital-based; *n*, number; NA, not applicable; OC, other cancer; PB, population-based; PCR, polymerase chain reaction.

### rs746868 {#sec3-2-3}

The pooled results based on four included studies \[[@B18],[@B25]\] (including 1351 cases and 2145 controls) indicated that no significant association between rs746868 polymorphism and risk of cancer was uncovered. Moreover, in the subgroup analysis by cancer type, ethnicity and source of control, similar results were found. (Supplementary Table S2).

### rs909253 {#sec3-2-4}

The pooled results based on 21 included studies \[[@B13],[@B18]\] (including 7022 cases and 8968 controls) indicated that no significant association between rs909253 polymorphism and cancer risk was found. However, in the stratification analysis by cancer type, we observed that rs909253 polymorphism was significantly related to an increased risk of HCC in allelic contrast (B vs A: OR = 3.52, 95% CI = 2.73--4.54, *P*=0.000, [Figure 4](#F4){ref-type="fig"}), dominant model (BB+AB vs AA: OR = 4.33, 95% CI = 3.07--6.09, *P*=0.000) and recessive model (BB vs AA+AB: OR = 4.92, 95% CI = 2.92--8.29, *P*=0.000). In addition, in the stratification analysis by ethnicity, we observed that rs909253 polymorphism was significantly related to an increased risk of Caucasian ethnicity in allelic contrast (B vs A: OR = 1.10, 95% CI = 1.02--1.20, *P*=0.019), and mixed ethnicity in allelic contrast (B vs A: OR = 1.09, 95% CI = 1.01--1.17, *P*=0.024), dominant model (BB+AB vs AA: OR = 1.11, 95% CI = 1.01--1.23, *P*=0.039). Moreover, in the stratification analysis by source of control, genotyping and HWE, null result was found ([Table 5](#T5){ref-type="table"}).

![Forest plot of *LTA* rs909253 polymorphism and cancer risk in allelic contrast stratified by cancer type\
Abbreviations: GC, gastric cancer; HCC, hepatocellular carcinoma; OC, other cancer.](bsr-40-bsr20192320-g4){#F4}

###### Meta-analysis of rs909253

  Variables           *n*   Allele contrast            Dominant model   Recessive model                                                      
  ------------------- ----- -------------------------- ---------------- -------------------------- -------------- -------------------------- --------------
  Total               21    0.349, 1.07 (0.93, 1.23)   0.000, 86.5%     0.198, 1.12 (0.94, 1.34)   0.000, 84.2%   0.993, 1.00 (0.81, 1.23)   0.000, 73.9%
  Cancer type                                                                                                                                
  NHL                 9     0.717, 0.98 (0.87, 1.10)   0.001, 68.2%     0.599, 1.04 (0.91, 1.18)   0.056, 47.3%   0.360, 0.90 (0.71, 1.13)   0.004, 64.2%
  GC                  5     0.567, 0.94 (0.78, 1.15)   0.006, 72.6%     0.775, 0.96 (0.74, 1.25)   0.007, 71.6%   0.511, 0.87 (0.57, 1.32)   0.005, 73.4%
  HCC                 2     0.000, 3.52 (2.73, 4.54)   0.959, 0.0%      0.000, 4.33 (3.07, 6.09)   0.928, 0.0%    0.000, 4.92 (2.92, 8.29)   1.000, 0.0%
  OC                  5     0.968, 0.99 (0.69, 1.43)   0.001, 79.8%     0.759, 1.11 (0.58, 2.13)   0.000, 87.7%   0.638, 0.93 (0.70, 1.25)   0.555, 0.0%
  Ethnicity                                                                                                                                  
  Asian               11    0.707, 1.07 (0.75, 1.54)   0.000, 92.9%     0.507, 1.17 (0.74, 1.86)   0.000, 91.3%   0.753, 0.92 (0.56, 1.52)   0.000, 85.4%
  Caucasian           6     0.019, 1.10 (1.02, 1.20)   0.697, 0.0%      0.064, 1.15 (0.99, 1.34)   0.141, 39.6%   0.470, 1.07 (0.90, 1.27)   0.534, 0.0%
  Mixed               4     0.024, 1.09 (1.01, 1.17)   0.860, 0.0%      0.039, 1.11 (1.01, 1.23)   0.758, 0.0%    0.136, 1.12 (0.96, 1.31)   0.984, 0.0%
  Source of control                                                                                                                          
  PB                  13    0.066, 1.18 (0.99, 1.42)   0.000, 88.4%     0.069, 1.23 (0.98, 1.53)   0.000, 85.4%   0.225, 1.18 (0.90, 1.53)   0.000, 75.7%
  HB                  8     0.370, 0.91 (0.73, 1.12)   0.000, 80.3%     0.858, 0.97 (0.71, 1.34)   0.000, 81.8%   0.119, 0.76 (0.54, 1.07)   0.003, 67.3%
  Genotyping                                                                                                                                 
  PCR                 18    0.377, 1.08 (0.91, 1.27)   0.000, 88.5%     0.223, 1.14 (0.92, 1.40)   0.000, 86.5%   0.996, 1.00 (0.78, 1.27)   0.000, 77.7%
  TaqMan              3     0.706, 1.02 (0.90, 1.16)   0.957, 0.0%      0.649, 1.04 (0.88, 1.23)   0.846, 0.0%    0.929, 1.01 (0.78, 1.31)   0.927, 0.0%
  HWE                                                                                                                                        
  Y                   19    0.304, 1.08 (0.94, 1.24)   0.000, 85.8%     0.292, 1.10 (0.92, 1.30)   0.000, 82.5%   0.643, 1.05 (0.85, 1.29)   0.000, 71.5%
  N                   2     0.985, 1.01 (0.32, 3.21)   0.000, 95.2%     0.592, 1.72 (0.24, 12.6)   0.000, 95.8%   0.403, 0.58 (0.16, 2.10)   0.003, 88.6%

Abbreviations: GC, gastric cancer; HB, hospital-based; HCC, hepatocellular carcinoma; *n*, number; N, no; OC, other cancer; PB, population-based; PCR, polymerase chain reaction; Y, yes.

Sensitivity analysis and publication bias {#sec3-3}
-----------------------------------------

Sensitivity analysis were performed to evaluate the influence of each separate case--control study. The results showed that there was no material alteration in corresponding pooled ORs for rs1041981, rs2229094, rs2239704, rs746868, rs909253 (Supplementary Figures S1--S5). In addition, Begg's test and Egger's regression test were performed to evaluate the publication bias. As for rs1041981, rs2229094, rs2239704, rs746868 and rs909253, no evidence of publication bias was identified (Supplementary Table S3).

TSA {#sec3-4}
---

To evaluate random errors, we performed TSA ([Figure 5](#F5){ref-type="fig"}). This analysis showed that the cumulative z-curve did not cross the trial sequential monitoring boundary and the required information size, suggesting that more evidences are needed to verify the conclusions.

![TSA for *LTA* rs909253 polymorphism under the allele contrast model](bsr-40-bsr20192320-g5){#F5}

Discussion {#sec4}
==========

In the present study, a total of 24 articles including 43 case--control studies were enrolled to validate the association between five *LTA* gene polymorphisms (rs1041981, rs2229094, rs2239704, rs746868, rs909253) and the risk of cancer. We identified that rs2239704 was inversely associated with the risk of cancer under different genetic models. However, for *LTA* rs1041981, rs2229094, rs746868, rs909253 polymorphisms, no significant association with cancer risk was uncovered.

In subgroup meta-analysis stratified by cancer type, we found that rs2239704 was significantly reduced NHL susceptibility. Huang et al. reported rs2239704 polymorphism was correlated with cancer and positive association in North Americans \[[@B35]\]. However, they included studies that contained buccal samples for SNP analysis or insufficient data studies \[[@B37]\]. We strictly follow the inclusion and exclusion criteria to include the literature. And our results indicated that rs2239704 was significantly reduced cancer susceptibility in mixed ethnicity, hospital-based control and polymerase chain reaction (PCR) genotyping subgroups. Despite of several possible bias, we still could conclude that rs2239704 could reduce cancer susceptibility.

In the stratified analysis of rs1041981, we found that Asians might have less susceptibility to cancer. Unlike the study by Huang et al. \[[@B35]\], we excluded two studies, one of which was autopsy specimen for SNP analysis \[[@B10]\] and the other was a study of HIV-infected patients \[[@B40]\]. The literature thus incorporated has a better baseline consistency and is more reflective of the real situation. Our results were consistent with the results of Huang et al.\[[@B35]\]. Due to the small sample size, we were unable to evaluate the role of rs1041981 in Caucasians. Larger sample size studies are needed for further evaluation. However, based on the current studies, we might conclude that rs1041981 could reduce cancer susceptibility in Asians.

For *LTA* rs2229094 and rs746848, only four studies reported their relationship with cancer in each group. No significant results were found. Huang et al. reported positive association between rs2229094 and cancer risk \[[@B35]\], which could be the bias from report by Takei et al. \[[@B10]\]. Because of the small sample size, we could not draw any conclusions based on current literature.

Although the overall analysis of rs909253 indicated a null result for cancer risk, the risk of cancer for Caucasians and HCC susceptibility were significantly increased in the stratified analysis by ethnicity and cancer types. In addition, some of the control groups did not match HWE, we can not exclude the possibility that may cause the bias. Then, subgroup analysis by HWE showed that HWE status did not cause the bias of results. Huang et al. did not report the relationship of rs909253 and cancer risk, because it might be present in high linkage disequilibrium with other four SNPs \[[@B8],[@B9]\]. However, our results identified that the function of rs909253 was opposite to rs2239704 and rs1041981. So, further studies with larger sample size are required to identify the role of *LTA* rs909253 and the linkage disequilibrium with other SNPs.

In the present study, we have put great effort on carefully searching for eligible studies. In order to obtain more accurate and reliable results, we conducted a comprehensive search to verify more eligible studies. Then, we used NOS to evaluate the quality of the included studies, eliminate low-quality studies and improve overall research quality. In order to provide the sources of heterogeneity, subgroup analysis was performed by ethnicity, cancer type, source of controls, genotyping and so on. In addition, sensitivity analysis was used to confirm the stability of the studies. Egger's and Begg's tests were used to assess publication bias. However, several limitations in our study should be noted. First, small sample size limits the reliability of the results for some polymorphisms. Second, we just included the studies published in English, which may influence the effects of the polymorphisms. Third, we mainly evaluated the relationship between *LTA* polymorphisms with various cancers, and we could not get enough data for some cancer types. Fourth, we did not assess the linkage disequilibrium, which might not reflect the real function correctly. In future, more well-designed case--control studies are needed to investigate the functions of LTA polymorphisms.

Conclusion {#sec5}
==========

Our meta-analysis suggests that *LTA* rs2239704 polymorphism is inversely associated with the risk of cancer, as is *LTA* rs1041981 polymorphism in Asia. While, LTA rs909253 polymorphism is a risk factor for HCC in Caucasians. Further studies with larger sample size are needed to confirm these findings.
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CI

:   confidence interval

HWE

:   Hardy--Weinberg equilibrium

LTA

:   lymphotoxin-α

NHL

:   non-Hodgkin lymphoma

NOS

:   Newcastle--Ottawa scale

OR

:   odds ratio

SNP

:   single nucleic polymorphism

TNF

:   tumor necrosis factor

TSA

:   trial sequential analysis
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